Standard BioTools Reports $127.1M Q1 Net Income, Strong Cash Position, and Improved Operations
LAB is trading near its 52-week low of $0.87 (14% above the low).
Summary
Standard BioTools reported a Q1 2026 net income of $127.1 million and a strong cash balance of $550 million, reflecting the successful divestiture of its SomaScan business and significant operational improvements.
Key Events · Earnings and Guidance · LAB
-
Reports $127.1 Million Q1 Net Income
The company reported a net income of $127.1 million for Q1 2026, a significant turnaround from a net loss of $26.0 million in the prior year, largely due to the gain on the sale of its SomaScan business.
-
Achieves Strong Cash Position
Cash and investments reached approximately $550 million as of March 31, 2026, providing substantial capital for future strategic initiatives and inorganic growth.
-
Significant Operational Improvement
Operating loss decreased by 54% and adjusted EBITDA improved by 78% year-over-year, demonstrating effective cost savings and progress towards profitability.
-
Maintains Full Year 2026 Revenue Outlook
The company reiterated its full-year 2026 revenue guidance in the range of $80 million to $85 million.
Analysis · LAB · Industrial Applications And Services
Standard BioTools Inc. reported a significant financial turnaround in Q1 2026, driven by a substantial net income of $127.1 million, primarily from the divestiture of its SomaScan business. This filing confirms the successful execution of the company's strategic initiatives, resulting in a robust cash and investments balance of approximately $550 million. The company also demonstrated strong operational improvements, with a 54% reduction in operating loss and a 78% improvement in adjusted EBITDA year-over-year, reinforcing its path to profitability. This strong financial position provides substantial flexibility for future inorganic growth strategies.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 49.5% of the 218 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $382.2M. The 52-week trading range was $0.87 to $1.72. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.